Guidelines and critical pathways for severe hospital-acquired pneumonia.

Hospital-acquired pneumonia (HAP) is associated with high morbidity and mortality. Early, appropriate, and adequate empiric therapy can increase the chance of survival. In 1995, the American Thoracic Society provided guidelines for the initial treatment of immunocompetent HAP patients, which is one of the principal HAP management approaches available to physicians today. However, these guidelines have several important limitations, including a lack of recommendations for duration of therapy and no recognition of newer drugs such as cefepime, trovafloxacin, and meropenem. Furthermore, they fail to distinguish among similar compounds (ie, beta-lactam/beta-lactamase inhibitor combinations) or to recommend specific antibiotics. The clinician using these guidelines needs to address local patterns of antimicrobial resistance, especially in ICUs. Effective computerized antibiotic management programs that incorporate information on local patterns of antimicrobial resistance can assist physicians in empiric therapy decision making, improve patient quality of care, and reduce medical costs.

[1]  R. Moore,et al.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. , 1984, The American journal of medicine.

[2]  S. Medendorp,et al.  High-Level Aminoglycoside-Resistant Enterococci: Colonization of Nursing Home and Acute Care Hospital Patients , 1987 .

[3]  T. Clemmer,et al.  A computer-assisted management program for antibiotics and other antiinfective agents. , 1998, The New England journal of medicine.

[4]  M. Niederman.  Gram-negative colonization of the respiratory tract: pathogenesis and clinical consequences. , 1990, Seminars in respiratory infections.

[5]  L E Nilsson,et al.  Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. , 1999, JAMA.

[6]  J. Dorca,et al.  Risk factors for nosocomial Legionella pneumophila pneumonia. , 1994, American journal of respiratory and critical care medicine.

[7]  R. Rodríguez-Roisín,et al.  Nosocomial pneumonia. A multivariate analysis of risk and prognosis. , 1988, Chest.

[8]  J. Rello,et al.  Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. , 1990, The American review of respiratory disease.

[9]  J. Rello,et al.  Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. , 1993, Chest.

[10]  M. Niederman,et al.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. , 1997, Chest.

[11]  L. Mandell,et al.  Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A consensus statement , 1996 .

[12]  J. Rello,et al.  Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. , 1994, American journal of respiratory and critical care medicine.

[13]  V L Yu,et al.  Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. , 1993 .

[14]  M. Pfaller,et al.  Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Solomkin,et al.  Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. , 1999, The Journal of antimicrobial chemotherapy.

[16]  F Gouin,et al.  Bronchoscopic or Blind Sampling Techniques for Diagnosis of Ventilator‐Associated Pneumonia , 1996, American journal of respiratory and critical care medicine.

[17]  R A Weinstein,et al.  Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. , 1999, JAMA.

[18]  M. Guiguet,et al.  Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients. , 1988, The American review of respiratory disease.

[19]  J. Bartlett,et al.  Bacteriology of hospital-acquired pneumonia. , 1986, Archives of internal medicine.

[20]  David Classen,et al.  Implementing Antibiotic Practice Guidelines through Computer-Assisted Decision Support: Clinical and Financial Outcomes , 1996, Annals of Internal Medicine.

[21]  R. Moellering,et al.  Antimicrobial-drug resistance. , 1996, The New England journal of medicine.

[22]  J. Chastre,et al.  Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. , 1989, The American review of respiratory disease.

[23]  R. Rodríguez-Roisín,et al.  Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. , 1990, The American review of respiratory disease.